Skip to Content
Morningstar

Grifols SA ADR GRFS

Morningstar Rating
Unlock
Stock XNAS Rating as of
$6.48 +0.18 (2.86%)
View Full Chart
As of Delayed Price Post-Trading: $6.48 0.00
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Grifols' Plasma Business Is Recovering From Pandemic Headwinds and Supports a Narrow Moat

Karen Andersen

Market share in the global plasma-derived protein business is concentrated among a small number of global players. Grifols lifted itself to the level of competitors Takeda and CSL with the $3.7 billion acquisition of Talecris in 2011. Over the past several years, the firm has been fighting competition and coronavirus pandemic headwinds with acquisitions and investments to build plasma collection and fractionation capacity, support its portfolio and pipeline, and expand geographically.

Read Full Report

Price vs Fair Value

View History
GRFS is trading at a 47% discount.
Price
$6.30
Fair Value
$81.70
Uncertainty
Very High
1-Star Price
$55.43
5-Star Price
$4.20
Economic Moat
Jmscx
Capital Allocation
Fhwttqygn

Bulls Say, Bears Say

Bulls

Grifols is one of the leading producers of plasma products globally. Multiple products allow Grifols to use plasma efficiently, reducing production costs.

Bears

Recombinant versions of Grifols' hemophilia products have eroded sales, and anti-FcRn therapies are entering late-stage testing that could threaten 40% of the immunoglobulin market.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GRFS is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$6.30
Day Range
$6.43–6.66
52-Week Range
$5.30–12.15
Bid/Ask
$6.38 / $6.75
Market Cap
$4.40 Bil
Volume/Avg
3.4 Mil / 2.2 Mil

Key Statistics

Price/Earnings (Normalized)
24.50
Price/Sales
0.60
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Mid Core
Total Number of Employees
23,700
Website
https://www.grifols.com

Competitors

Valuation

View More
Metric
GRFS
CSL
PFE
Price/Earnings (Normalized)
 24.5028.4314.27
Price/Book Value
 0.665.281.67
Price/Sales
 0.606.322.53
Price/Cash Flow
 6.8532.9913.63
Price/Earnings
GRFS
CSL
PFE

Financial Strength

Metric
GRFS
CSL
PFE
Quick Ratio
 0.720.950.58
Current Ratio
 2.482.150.91
Interest Coverage
 1.287.210.74
Quick Ratio
GRFS
CSL
PFE

Profitability

Metric
GRFS
CSL
PFE
Return on Assets (Normalized)
 1.30%8.11%4.98%
Return on Equity (Normalized)
 4.69%18.17%10.90%
Return on Invested Capital (Normalized)
 3.45%10.94%7.28%
Return on Assets
GRFS
CSL
PFE
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Drug Manufacturers - General Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
LLY
Eli Lilly and CoDsjvtxwpHhzxg$695.3 Bil
JNJ
Johnson & JohnsonRqfxgjkyxXvsd$359.3 Bil
MRK
Merck & Co IncRdwxlbhDsln$321.5 Bil
ABBV
AbbVie IncVmzxhrdbHvwj$297.3 Bil
AZN
AstraZeneca PLC ADRLhptpbxvkHmmv$215.8 Bil
RHHBY
Roche Holding AG ADRQbpmzqctkHbpt$199.7 Bil
NVS
Novartis AG ADRDqlhhrfFttls$196.0 Bil
PFE
Pfizer IncLppzzrtdRvxg$148.7 Bil
AMGN
Amgen IncDkxpdtqqssWrjf$145.8 Bil
SNY
Sanofi SA ADRSmjfkvysdYbsd$117.3 Bil

Sponsor Center